SCHEMBL3135380

SCHEMBL3135380

CC(=O)c1ccc(CC(=O)OC(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
LMNA P02545 3/20 0.47
RIPK1 Q13546 1/20 0.46
RIPK3 Q9Y572 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
MAPT P10636 4/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
EPHX2 P34913 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
MAOB P27338 5/20 0.44
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAOA P21397 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745549 0.87 ALDH1A1 (0.50) KMT2ALMNARIPK1RIPK3MTNR1A
SCHEMBL4961300 0.86 MTNR1A (0.47) KMT2ALMNARIPK1RIPK3MTNR1A
SCHEMBL27700413 0.84 KMT2A (0.57) KMT2ALMNARIPK1RIPK3MTNR1A
SCHEMBL2650122 0.84 LOXL2 (0.54) KMT2ALMNARIPK1RIPK3MTNR1A
SCHEMBL31074037 0.84 KMT2A (0.55) KMT2ALMNAMTNR1AMTNR1BMAPT
SCHEMBL19085086 0.83 MTNR1A (0.47) LMNARIPK1RIPK3MTNR1AMTNR1B
SCHEMBL21554546 0.83 CA2 (0.50) LMNAMTNR1AMTNR1BALDH1A1EPHX2
SCHEMBL1283948 0.83 CA2 (0.50) LMNARIPK1RIPK3MTNR1AMTNR1B
SCHEMBL7517689 0.83 HPGD (0.50) KMT2ARIPK1RIPK3MTNR1AMTNR1B
SCHEMBL13141325 0.83 RIPK1 (0.43) KMT2ALMNARIPK1RIPK3MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-11-02 US disclosed
EP-4234552-A2 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-3426244-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-12-27 US disclosed
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2022-01-20 US disclosed
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 US disclosed
EP-3426244-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics Inc. (US) 2019-01-16 EP disclosed
WO-2017156179-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed
EP-2099776-B1 CHELATING AGENT UNIV MUENCHEN TECH (DE) 2015-10-07 EP disclosed
EP-2099776-B1 CHELATING AGENT UNIV MUENCHEN TECH (DE) 2015-10-07 EP disclosed
US-20100081799-A1 Chelating Agent TECHNISCHE UNIVERSITAT MUNCHEN (DE) 2010-04-01 US disclosed
US-20100081799-A1 Chelating Agent TECHNISCHE UNIVERSITAT MUNCHEN (DE) 2010-04-01 US disclosed
CN-101605768-A Sequestrant UNIV MUENCHEN TECH (DE) 2009-12-16 CN disclosed
EP-2099776-A1 CHELATING AGENT Technische Universität München (DE) 2009-09-16 EP disclosed
WO-2008068516-A1 CHELATING AGENT Technische Universität München (DE) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD KMT2A 2306/4885LMNA 3385/4885RIPK1 3600/4885
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD KMT2A 2306/4885LMNA 3385/4885RIPK1 3600/4885
US-20100081799-A1 Chelating Agent HRH3, C3AR1, H1-3 KMT2A 365/4885LMNA 4046/4885RIPK1 2876/4885
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD KMT2A 2306/4885LMNA 3385/4885RIPK1 3600/4885
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD KMT2A 2306/4885LMNA 3385/4885RIPK1 3600/4885
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD KMT2A 2306/4885LMNA 3385/4885RIPK1 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.